Creative Medical Technology (NASDAQ:CELZ) Stock Price Up 5.3% – Time to Buy?

Shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) shot up 5.3% during mid-day trading on Monday . The stock traded as high as $2.23 and last traded at $2.17. 30,890 shares changed hands during mid-day trading, a decline of 39% from the average session volume of 50,695 shares. The stock had previously closed at $2.06.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Creative Medical Technology in a research note on Friday, May 22nd. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce”.

Creative Medical Technology Stock Performance

The firm has a market cap of $7.81 million, a price-to-earnings ratio of -0.99 and a beta of 1.84. The firm’s 50 day moving average is $2.22 and its 200-day moving average is $2.12.

Creative Medical Technology (NASDAQ:CELZ) last released its earnings results on Friday, May 8th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.01. As a group, research analysts predict that Creative Medical Technology Holdings, Inc. will post -1.57 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC bought a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned about 1.17% of Creative Medical Technology at the end of the most recent reporting period. 1.42% of the stock is owned by hedge funds and other institutional investors.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.